Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Beth Israel Deaconess Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00179582
First received: September 13, 2005
Last updated: May 26, 2010
Last verified: May 2010

September 13, 2005
May 26, 2010
Not Provided
Not Provided
Global improvement in IBS symptoms
Same as current
Complete list of historical versions of study NCT00179582 on ClinicalTrials.gov Archive Site
  • Frequency of bowel movements
  • Changes in abdominal pain
  • Changes in bloating
Same as current
Not Provided
Not Provided
 
Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS
A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients

To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
IBS
Drug: VSL#3
Not Provided
Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr. 2005 Jul 26; [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
180
Not Provided
Not Provided

Inclusion Criteria:

  • IBS diarrhea

Exclusion Criteria:

  • < 18 years of age
  • Pregnancy/breast feeding
  • concomitant medications to reduce bowel function
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00179582
2004P-000001, VSL1
Not Provided
Not Provided
Beth Israel Deaconess Medical Center
Not Provided
Principal Investigator: Anthony Lembo, MD Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP